Skip to Content
Merck
CN
All Photos(1)

Documents

475846

Sigma-Aldrich

MIF Antagonist III, 4-IPP

Sign Into View Organizational & Contract Pricing

Synonym(s):
MIF Antagonist III, 4-IPP, Macrophage Migration Inhibitory Factor Antagonist III, 4-IPP, 4-Iodo-6-phenylpyrimidine
Empirical Formula (Hill Notation):
C10H7IN2
CAS Number:
Molecular Weight:
282.08
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Assay

≥90% (HPLC)

Quality Level

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

amber

solubility

DMSO: 50 mg/mL

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H

InChI key

ZTCJXHNJVLUUMR-UHFFFAOYSA-N

General description

A cell-permeable iodo-pyrimidine compound that covalently modifies MIF N-terminal proline and exhibits higher MIF inhibitory potency than ISO-1 (Cat. No. 475837) in cell-free dopachrome tautomerase activity assays (IC50 ~5 vs. 50 µM, respectively, using recombinant human MIF) as well as in cell-based migration assays (50% vs 0% inhibition with respective inhibitor at 10 µM) and anchorage-independent growth (57% vs 0% inhibition with respective inhibitor at 10 µM) using human lung adenocarcinoma A549. Also shown to reduce A549 cellular active Rac1 population (50 µM, 16 h) in vitro and effectively decrease liver tautomerase activity by 50% in mice (1 mg/animal/day or ~50 mg/kg/day via i.p.) in vivo.
A cell-permeable iodo-pyrimidine compound that covalently modifies MIF N-terminal proline and exhibits higher MIF inhibitory potency than ISO-1 (Cat. No. 475837) in cell-free dopachrome tautomerase activity assays (IC50 ~5 vs. 50 µM, respectively, using recombinant human MIF) as well as in cell-based migration assays (50% vs 0% inhibition with respective inhibitor at 10 µM) and anchorage-independent growth (57% vs 0% inhibition with respective inhibitor at 10 µM) using human lung adenocarcinoma A549. Also shown to reduce A549 cellular active Rac1 population (50 µM, 16 h) in vitro and effectively decrease liver tautomerase activity by 50% in mice (1 mg/animal/day or ~50 mg/kg/day via i.p.) in vivo.

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Other Notes

Winner, M., et al. 2008. Cancer Res.68, 7253.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

WGK

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ricardo A de Azevedo et al.
Oncoimmunology, 9(1), 1846915-1846915 (2020-12-22)
Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients with metastatic melanoma, yet, durable complete response; even with Ipilimumab/Nivolumab combo are under 30%. Primary and acquired resistance in response to ICB is commonly due to a tumor immune

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service